

SEL Ophthalmology Pathways Outcomes and Monitoring Framework for Medical Retinal Treatment for Wet Age-Related Macular Degeneration (wet AMD)

Measures:

KPI	Intervention	Target/ Standard	Measure	Data Source	Who Measures	Frequency of reporting (in any financial year)
1.	Audit of best value treatment choice for naïve patients with wet AMD (aflibercept 2mg or ranibizumab)	90% of new initiations for intravitreal treatment to follow the local SEL pathway choices and use the best value intravitreal treatment	<p>(x) the number of new starter patients initiated on a first line intravitreal treatment as outlined in the pathway for wet AMD</p> <p>(y) the total number of new starter patients initiated on intravitreal treatment for wet AMD</p> <p>$[x/y] \times 100$ = the percentage of new starter patients initiated on a first line intravitreal treatment for wet AMD*</p> <p>*Reasons for deviating from the local SEL pathway choices and preferred best value intravitreal treatment to be outlined</p>	Trust database	Trusts	Annual (snapshot audit)
2.	Audit on patients being initiated on treatment outside of NICE TA guidance (evidence of late AMD (wet active) and visual acuity better than 6/12)	100% of patients to comply with the local SEL pathway	<p>Audit to demonstrate:</p> <ul style="list-style-type: none"> a) Total number of patients initiated on treatment* b) Compliance with pathway including the criteria for treating under this section of the pathway (100%) c) Number of patients who have achieved optimal response as outlined in the wAMD pathway d) Number of patients stopped (and broad themes on reasons) <p>*Reasons for deviating from the local SEL pathway choices and preferred best value biologic to be outlined</p>	Trust database	Trusts	Annual

Not to be used for commercial or marketing purposes. Strictly for use within the NHS

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care System: NHS South East London (covering the boroughs of Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust

3.	Audit on patients initiated on treatment with aflibercept 8mg or faricimab intravitreal injections	100% of patients to comply with the local SEL pathway	Audit to demonstrate: <ul style="list-style-type: none"> a) Total number of patients initiated on treatment with aflibercept 8mg intravitreal injections* b) Total number of patients initiated on treatment with faricimab intravitreal injections* c) Compliance with wet AMD pathway including the criteria for treating d) Number of patients who have achieved optimal response in line with wAMD pathway e) Number of patients on aflibercept 8mg or faricimab achieving treat and extend intervals greater than 12 weeks f) Number of patients stopped (and broad themes on reasons) *Reasons for deviating from the local SEL pathway choices to be outlined	Trust database	Trusts	Annual (snapshot audit)
4.	Measure impact of the pathway on overall service commissioning costs to ensure value for money	High-Cost drugs use (biologics) in SEL	Breakdown of biologic use and cost by indication at regular intervals by Trust, for SEL ICB	Acute activity (finance reporting)	SEL ICB (Business Intelligence + Trust high-cost drug reporting)	Quarterly

Approved by:

SEL Ophthalmology pathway group: September 2025

SEL Integrated Medicines Optimisation Committee: September 2025

Review date: April 2026 (or sooner if indicated)

References:

1. National Institute for Health and Care Excellence (NICE), *Age-related macular degeneration. NICE guideline [NG82]*. 2018. <https://www.nice.org.uk/guidance/ng82> [Accessed July 2025]

Not to be used for commercial or marketing purposes. Strictly for use within the NHS

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care System: NHS South East London (covering the boroughs of Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust